few months ''tax loss for many for 2014 ''if you sell''
Recruiting Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy Condition: Muscular Dystrophy, Duchenne
Intervention: Drug: eteplirsen
2 Recruiting Phase I/II Study of SRP-4053 in DMD Patients Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Placebo; Drug: SRP-4053
3 Recruiting Confirmatory Study of Eteplirsen in DMD Patients Condition: Duchenne Muscular Dystrophy (DMD)
Intervention: Drug: eteplirsen injection
It is no other dmd treatment this effective no matter what, Sarepta is the only real dmd player near term.Even if the drug is only delaying any at all it is still the only effective drug.
Big money is doing this...Rico 1.5 billion a year drug treatment short term in dmd ''aint no other drug with any benefits but this one.
that charge for patented drugs ''You can't do that unless it is the only treatment.You have other drugs out there but not the number one treatment like gild.I say it is up to gild what they want to charge flat out.
we will see what the real motives are any day now...
1. shake out to buy shares
2. End of year tax selling
3. just being restless owning shares
4. 168 week data leak and weak ''they think'' but not really''
People must remember ,this is the only real dmd treatment that works the best no matter how it turns out.
It is nothing else out there even close to working for the treatment of dmd. '' nothing but this drug''
we are at a 52 week low and have 3 years of dmd under our belt,I also have seen this on a pile of other small cap stocks.Makes me think all was pre-planned for the large money holders.
I might be over thinking but think about this..
Biomarin has talks with Sarepta first ,Biomarin buys RNA and when that deal closes we may see a partnership between Sarepta and Biomarin then..sure would make sense.
for Sarepta for exon 51 only.A patent fix along with Sarepta keeping all the other exons in Europe.
Remember Sarepta has the only real treatment for dmd even if declines of any kind comes in to play .It is my opinion this drug should be dosed daily in the future with a personal pump system.My studies make me think if you keep this at a constant level you will have the maxium effect.
repeat the seesaw words all over again
1.Sarepta is INCORP in Delaware not MASS.
2.The lawsuit makes claims of what the FDA passed on to Sarepta.
Lawsuit has no merit and once it is placed in delaware that court will no alow it.
close to the 52 week low and we have 3 years of dmd data ...this is nothing more than a way to get the price down super low and then advance the stock price many times for 2015'' greedy greedy firms.
They have already did this to many other biotechs already .I am buying anything under 15.00 a share for long term that i can.
The U.S. drugmaker said on Monday it was establishing a gene therapy platform to study potential treatments, led by a top UK expert, and had struck a deal with privately owned U.S. biotech firm Spark Therapeutics to develop a treatment for haemophilia.
The Spark program is expected to enter early-stage clinical trials for haemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with Pfizer taking over late-stage studies, any regulatory approvals and potential commercialization.
Spark will get $20 million upfront and be eligible for additional payments based on product success worth up to $260 million.
Pfizer's research effort in gene therapy will be led by Michael Linden, a professor from King’s College London and director of the University College London Gene Therapy Consortium. Linden is joining Pfizer on a two-year secondment.
Gene therapy has seen more than 20 years of experiments but research has been dogged by a series of disappointments and safety concerns.
Now, however, scientists have solved some of the earlier problems and treatments